blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4074702

EP4074702 - CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  01.09.2023
Database last updated on 07.10.2024
FormerRequest for examination was made
Status updated on  21.04.2023
FormerThe application has been published
Status updated on  16.09.2022
Most recent event   Tooltip01.09.2023Application deemed to be withdrawnpublished on 04.10.2023  [2023/40]
Applicant(s)For all designated states
Pfizer Products Inc.
Eastern Point Road
Groton, CT 06340 / US
[2022/42]
Inventor(s)01 / CAMPETA, Anthony, Michael
Groton, CT 06340 / US
02 / CHEKAL, Brian, Patrick
Groton, CT 06340 / US
03 / MCLAUGHLING, Robert, William
Groton, CT 06340 / US
04 / SINGER, Robert, Alan
Groton, CT 06340 / US
 [2022/42]
Representative(s)Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
[2022/42]
Application number, filing date22171745.725.03.2008
[2022/42]
Priority number, dateUS20070910379P05.04.2007         Original published format: US 910379 P
US20070976546P01.10.2007         Original published format: US 976546 P
US2008003155426.02.2008         Original published format: US 31554
[2022/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4074702
Date:19.10.2022
Language:EN
[2022/42]
Search report(s)(Supplementary) European search report - dispatched on:EP16.09.2022
ClassificationIPC:C07D401/06, A61K31/4439, A61P35/00
[2022/42]
CPC:
C07D401/06 (EP,CN,KR,US); A61K31/4439 (KR); A61P35/00 (EP);
A61P35/02 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2023/21]
Former [2022/42]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:ZUR BEHANDLUNG VON ABNORMEM ZELLWACHSTUM BEI SÄUGETIEREN GEEIGNETE KRISTALLINE FORMEN VON 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOL[2022/42]
English:CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS[2022/42]
French:FORMES CRISTALLINES DE 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE UTILES POUR LE TRAITEMENT D'UNE CROISSANCE CELLULAIRE ANORMALE CHEZ DES MAMMIFERES[2022/42]
Examination procedure19.04.2023Examination requested  [2023/21]
19.04.2023Date on which the examining division has become responsible
20.04.2023Application deemed to be withdrawn, date of legal effect  [2023/40]
16.05.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time  [2023/40]
Parent application(s)   TooltipEP08719405.6  / EP2134702
EP17168752.8  / EP3252047
Divisional application(s)EP23167662.8  / EP4249063
Fees paidRenewal fee
05.09.2022Renewal fee patent year 03
05.09.2022Renewal fee patent year 04
05.09.2022Renewal fee patent year 05
05.09.2022Renewal fee patent year 06
05.09.2022Renewal fee patent year 07
05.09.2022Renewal fee patent year 08
05.09.2022Renewal fee patent year 09
05.09.2022Renewal fee patent year 10
05.09.2022Renewal fee patent year 11
05.09.2022Renewal fee patent year 12
05.09.2022Renewal fee patent year 13
05.09.2022Renewal fee patent year 14
05.09.2022Renewal fee patent year 15
31.03.2023Renewal fee patent year 16
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]US2006094763  (YE QIANG [US], et al);
 [YD]WO2006123223  (PFIZER [US], et al);
by applicantUS6531491
 US6534524
 US2004224988
 US2006091067
 US2006094763
 US2006094881
 WO2006048745
 WO2006123223
 US7232910
 US2007203196
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.